Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP9RBK)

Drug Name

WZ4003 Drug Info

Synonyms

WZ-4003

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 72200024
CAS Number: CAS 1214265-58-3
TTD Drug ID: DMP9RBK

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Omphalocele kinase 1 (NUAK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID22564207C25b	DMBMYKQ	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Drug(s) Affected By NUAK family SNF1-like kinase 1 (NUAK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[3]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[5]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[6]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[7]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[8]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[8]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[9]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[10]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NUAK family SNF1-like kinase 2 (NUAK2)	TTHVOTQ	NUAK2_HUMAN	Inhibitor	[1]
Omphalocele kinase 1 (NUAK1)	TT65FL0	NUAK1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
NUAK family SNF1-like kinase 1 (NUAK1)	OTLLHJJQ	NUAK1_HUMAN	Drug Response	[1]

------------------------------------------------------------------------------------

References

1	Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem J. 2014 Jan 1;457(1):215-25.
2	Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93.
3	DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
4	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
5	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
6	Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
7	Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
8	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
9	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
10	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.